Price
$4.36
Decreased by -0.91%
Dollar Volume (20D)
234.93 K
ADR%
5.79
Earnings Report Date (estimate)
Nov 13, 23 (-0.34)
Market Cap.
92.02 M
Shares Float
20.87 M
Shares Outstanding
21.11 M
Beta
1.53
Price / Earnings
-1.43
BPR
0.17
20D Range
4.21 5.52
50D Range
4.21 5.89
200D Range
2.36 10.30
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 15, 23 -0.43
Increased by +68.15%
-0.42
Decreased by -2.38%
Aug 14, 23 0.43
Increased by +139.81%
0.41
Increased by +4.88%
May 9, 23 -0.50
Increased by +37.50%
-0.65
Increased by +23.08%
Mar 16, 23 -0.83
Decreased by -9.21%
-0.83
Nov 14, 22 -1.35
Decreased by -90.14%
-1.13
Decreased by -19.47%
Aug 11, 22 -1.08
Increased by +29.41%
-0.83
Decreased by -30.12%
May 12, 22 -0.80
Increased by +38.46%
-0.81
Increased by +1.23%
Mar 10, 22 -0.76
Increased by +31.53%
-0.69
Decreased by -10.14%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 0.00
Decreased by N/A%
-8.24 M
Increased by +24.22%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-9.56 M
Decreased by -20.77%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-10.99 M
Decreased by -52.91%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-13.56 M
Decreased by -102.72%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-10.87 M
Increased by +3.86%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-7.92 M
Increased by +0.89%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-7.19 M
Decreased by -52.85%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-6.69 M
Decreased by -77.78%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.